Sandoz Group AG SDZ.SW
Composite 41/100; the shares have moved about 30% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 31/100 — a moderate mark against it.
Momentum ranks 62/100 — a slight point in its favour.
Growth ranks 31/100 — a moderate mark against it. Valuation ranks 36/100 — a moderate mark against it. Quality ranks 40/100 — a slight mark against it.
What the company does Sandoz Group AG develops, manufactures, and markets generic and biosimilar drugs across therapeutic areas including cardiovascular, oncology, and rare diseases. It also supplies active pharmaceutical ingredients and finished dosage forms globally.
Key financials Revenue grew 10.7% with EPS up 149.5%. Margins: gross 47.5%, operating 14.3%, net 8.2%. ROE 10.4%, ROA 4.3%, ROCE 10.3%. Debt/Equity 0.61, net debt/EBITDA 2.09, current ratio 1.18.
Stock health Sandoz scores average quality (52.1) but strong growth (87.7) and momentum (69.8). Piotroski F-Score 7/9, Altman Z 2.99. RSI(14) 52.90; 12-month return 42.22%, down 9.72% from 52-week high.
Price vs fair value The stock trades at a PREMIUM of 13.30% versus our fair-value estimate of 58.49 and at a discount of 4.30% versus the 12-month target of 70.36. - Forward P/E 17.30 vs trailing 38.04 (Valuation) - PEG 0.14 signals deep undervaluation vs peers (Valuation) - Growth score 87.7 supports premium (Growth) - Momentum score 69.8 and 12-month return 42.22% (Momentum)
Looking forward Analysts expect continued EPS growth and margin stability. Debt metrics remain manageable, but valuation remains stretched relative to fair value. Momentum and growth support the premium, while the discount to target suggests potential upside if execution continues.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.